Abstract Search

ea0049gp65 | Developmental & Protein Endocrinology | ECE2017

3-year safety and efficacy Update of the VERTICAL & VISTA trials of somavaratan (VRS-317), a long-acting rhGH, in children with Growth Hormone Deficiency (GHD)

Miller Bradley S. , Moore Wayne V. , Fechner Patricia Y. , Van Meter Quentin L. , Fuqua John S. , Ng David , Humphriss Eric , Charlton R. William , Bright George M.

Requirement for daily rhGH injections is a treatment burden that can compromise adherence and efficacy in patients with GHD. Somavaratan is a novel long-acting rhGH fusion protein in clinical development for pediatric and adult GHD. In a multicenter, randomized Phase 1b/2a study, somavaratan significantly improved height velocity (HV) and IGF-I in pre-pubertal children with GHD. Preliminary efficacy and safety in subjects who have completed 3 years of somavaratan treatment are...

0 shares

Endocrine Abstracts

3-year safety and efficacy Update of the VERTICAL & VISTA trials of somavaratan (VRS-317), a long-acting rhGH, in children with Growth Hormone Deficiency (GHD)

BiosciAbstracts